AI
RYTM icon

Axiom Investors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Axiom Investors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.65M Sell
86,880
-4,869
-5% -$440K 0.08% 87
2026
Q1 		$7.98M Buy
91,749
+8,195
+10% +$797K 0.09% 88
2025
Q4 		$8.94M Buy
83,554
+523
+0.6% +$55.5K 0.08% 87
2025
Q3 		$8.39M Buy
83,031
+30,571
+58% +$2.84M 0.06% 87
2025
Q2 		$3.31M Buy
+52,460
New +$3.21M 0.03% 107

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Axiom Investors's RYTM Position: Q2 2026 in Review

Axiom Investors reduced its Rhythm Pharmaceuticals (RYTM) stake by 5.3% in Q2 2026, selling an estimated $440K and leaving 86,880 shares worth $9.65M. The position accounts for 0.08% of the portfolio, ranked #87.

Axiom Investors first reported a position in RYTM in Q2 2025 and has held it in 5 quarters since. 305 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Axiom Investors held 86,880 shares of Rhythm Pharmaceuticals worth $9.65M as of Q2 2026.
  • Axiom Investors sold 4,869 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $440K.
  • Rhythm Pharmaceuticals made up 0.08% of Axiom Investors's portfolio in Q2 2026, its #87 holding.
  • Axiom Investors first reported a position in Rhythm Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 305 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Axiom Investors's 13F filing for Q2 2026, filed 12 Aug 2026.